What Conditions Can Cause a Low Platelet Count?

Thrombocytopenia—the medical term for an abnormally low platelet count—is not itself a disease but rather a laboratory finding that signals an underlying pathological process. Platelets, or thrombocytes, are small, anucleate blood cells essential for hemostasis; they adhere to damaged vessel walls, aggregate to form primary hemostatic plugs, and support coagulation factor activation. A normal platelet count ranges from 150,000 to 400,000 per microliter (µL) of blood. Clinically significant thrombocytopenia is generally defined as a count below 150,000/µL, with increased bleeding risk becoming more pronounced below 50,000/µL and spontaneous mucocutaneous bleeding—such as petechiae, purpura, epistaxis, or menorrhagia—often occurring when counts fall below 20,000/µL.

The causes of thrombocytopenia fall into three broad mechanistic categories: decreased production, increased destruction or consumption, and sequestration. Bone marrow disorders—including aplastic anemia, myelodysplastic syndromes, leukemia, lymphoma, and metastatic solid tumors—can impair megakaryocyte maturation and platelet release. Chemotherapy, radiation therapy, and certain medications (e.g., thiazide diuretics, sulfonamides, heparin, and valproic acid) may also suppress platelet production. Immune-mediated destruction underlies conditions such as immune thrombocytopenia (ITP), where autoantibodies target platelet glycoproteins, and drug-induced immune thrombocytopenia. Non-immune consumption occurs in disseminated intravascular coagulation (DIC), thrombotic microangiopathies (e.g., thrombotic thrombocytopenic purpura and hemolytic uremic syndrome), and severe sepsis. Splenomegaly—due to cirrhosis, lymphoproliferative disorders, or chronic infections—can lead to functional platelet sequestration and reduced circulating counts.

Diagnosis requires careful clinical correlation: a thorough history (including medication use, recent infections, family history), physical examination (looking for signs of bleeding, hepatosplenomegaly, or lymphadenopathy), and targeted laboratory testing—including complete blood count with peripheral blood smear review, reticulocyte count, coagulation studies, and, when indicated, bone marrow aspiration and biopsy. Treatment is directed at the underlying etiology: corticosteroids and intravenous immunoglobulin for acute ITP; discontinuation of offending drugs; supportive transfusion of platelet concentrates in life-threatening hemorrhage or prior to invasive procedures; and definitive therapies such as splenectomy, thrombopoietin receptor agonists, or rituximab in refractory cases. Prompt recognition and accurate classification of thrombocytopenia are critical—not only to prevent morbidity from bleeding complications but also to identify potentially serious hematologic, autoimmune, or malignant conditions requiring urgent intervention.